all

The NLA has published a scientific statement on the use of icosapent ethyl (IPE) in statin-treated patients that is based on the results of REDUCE-IT, the cardiovascular outcomes trial that examined the effects of IPE on major adverse cardiovascular events in high or very high-risk statin-treated patients with elevated triglycerides.

View the June 2019 SWLA E-Newsletter by clicking here. 

View the January 2019 SWLA E-Newsletter by clicking here.